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After being largely disregarded 
for decades, tumor immunology has 
recently come back into prominence, at 
least in part because of the approval by 
the US Food and Drug Administration 
(FDA) of a monoclonal antibody 
targeting cytotoxic T lymphocyte-
associated protein 4 (CTLA4) and the 
development of dendritic cell (DC)-
based therapies. There is widespread 
consensus on the notion that the optimal 
efficacy of these immunotherapeutic 
agents depends upon the elimination of 
immunosuppressive tumor-infiltrating 
cells. Indeed, malignant transformation 
is generally accompanied by the secretion 
of soluble factors that stimulate the 
production of immunosuppressive 
cells in the bone marrow and recruit 
them the tumor microenvironment. 
Immunosuppressive cells are involved in 
the regulation of a variety of processes, 
including angiogenesis, inflammation and 
immunosuppression. The most prominent 
bone marrow-derived cell population 
that exerts broadly immunosuppressive 
functions is constituted by myeloid-
derived suppressor cells (MDSC). These 
cells potently suppress both innate 
and adaptive immunity by inhibiting 
T-cell activation, suppressing natural 
killer (NK)-cell cytotoxicity, favoring the 
development of regulatory T cells (Tregs) 
and preventing the maturation of DCs.1
While Otto Warburg reported his 
milestone discovery more than 80 years 
ago,2 only recently has progress been 
made in understanding the role of 
metabolism in oncogenesis and tumor 
progression. Many tumor types are indeed 
characterized by enhanced glycolytic flux 
and convert a major fraction of pyruvate 
into lactate, even under normoxic 
conditions. The latter effect is mediated 
by lactate dehydrogenase A (LDHA), a 
hypoxia-inducible factor 1α (HIF-1α) 
target. It is clear that the Warburg effect 
serves to generate biosynthetic precursors, 
thus facilitating the survival and rapid 
proliferation of malignant cells.3 Is 
it possible that a tumor environment 
enriched in lactate also influences 
anticancer immune responses?
It has recently been suggested that 
the production of lactate by tumor cells 
impairs immune effectors by inhibiting 
the cytolytic functions of T cells and by 
polarizing immune responses toward a 
TH17/TH23 pro-inflammatory profile.4,5 
In addition, lactate is known to inhibit the 
maturation of DCs.6 Finally, our recent 
study adds lactate to the long list of cancer-
derived factors that stimulate the generation 
of MDSCs,7 which already included 
interleukin IL-1β, IL-6, granulocyte 
colony-stimulating factor (G-CSF), 
granulocyte monocyte colony stimulating 
factor (GM-CSF), prostaglandin E2 
(PGE2), tumor necrosis factor α (TNFα), 
and vascular endothelial growth factor 
(VEGF). In particular, lactate turned out 
to exacerbate immunosuppression (by 
increasing the frequency of MDSCs) and 
to limit the activity of innate immune 
effectors (by inhibiting the functions of 
NK cells), further demonstrating that 
lactate contributes to the establishment of 
an immunosuppressive microenvironment 
for developing tumors (Figure 1).7 
Moreover, a recent study suggests that 
lactate operates as an endogenous inhibitor 
of histone deacetylases,8 hence regulating 
(at the transcriptional level) a number 
of genes that not only are involved in 
metabolism and transcriptional control 
but also participate in immune responses, 
such as natural cytotoxicity triggering 
receptor 1 (NCR1), which encodes an 
NK-cell activating receptor. Since it has 
been reported that effector T cells and 
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Many malignant cells produce increased amounts of lactate, which promotes the development of myeloid-derived 
suppressor cells (MDsCs). MDsCs, lactate, and a low ph in the tumor microenvironment inhibit the function of natural 
killer (NK) cells and T lymphocytes, hence allowing for disease progression. Ketogenic diets can deplete tumor-bearing 
animals from MDsCs and regulatory T cells, thereby improving their immunological profile.e26383-2  OncoImmunology  Volume 2 Issue 11
Tregs differ from each other with regard 
to bioenergetic metabolism, high levels of 
lactate (and/or the consequent decrease 
in microenvironmental pH) may affect 
these T-cell subsets in a different fashion.5 
We observed an increased frequency 
of T cells to infiltrate LDHA-deficient 
tumors as well as LDHA-proficient lesions 
developing in mice subjected to a ketogenic 
diet, a suboptimal surrogate for LDHA 
inhibition. These observations suggest that 
reduced levels of lactate may be associated 
with an improved survival or recruitment 
of effector T cells. Interestingly, a recent 
report demonstrates that a ketogenic diet 
lowers the levels of lactate in head and neck 
cancer lesions.9 It would be interesting 
to investigate how the kinetic of lactate 
reduction affects the generation of MDSCs 
and the overall immunological profile in 
this setting.
Several reports indicate that the pH of 
the tumor microenvironment can impact 
on antitumor immune responses.10 Our 
study also shows that lowering the local 
pH from 6.8 to 6.0 results in a significant 
decrease in the activity of NK cells. 
Moreover, by utilizing a system for the in 
vitro generation of MDSCs from mouse 
bone marrow cells, we demonstrated a 
decrease in the individual cytotoxic activity 
of NK cells against target cells at low pH.
In summary, our study highlights 
a role for tumor-derived lactate in the 
regulation of NK cells, MDSCs and 
Tregs, lending further support to the 
notion that tumor metabolism and 
immunity are tightly interconnected.
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Figure 1. Impact of lactate on tumor-infiltrating immune cells. Cancer cells acquire an altered metabolic state that involves increased glucose uptake 
and glycolytic metabolism in spite of normal oxygen availability. Cells adapting to this state often exhibit the upregulation of hypoxia-inducible factor 
1α (hIF-1α), in turn promoting the synthesis of glucose transporters (GLuTs) and monocarboxylate transporters (MCTs) to allow for glucose intake and 
lactate secretion, respectively. Increased lactate secretion results in the acidification of the tumor microenvironment and in the recruitment of increased 
amounts of myeloid-derived suppressor cells (MDsCs). MDsCs inhibit the activity of natural killer (NK) cells and T lymphocytes, skew the immune 
response toward a Th17 polarization and inhibit the maturation of dendritic cells (DCs). Lactate may also interfere with antitumor immune responses by 
affecting the transcription of histone deacetylase (hDaC)-regulated genes.
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